CU20230023A7 - Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer - Google Patents

Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer

Info

Publication number
CU20230023A7
CU20230023A7 CU2023000023A CU20230023A CU20230023A7 CU 20230023 A7 CU20230023 A7 CU 20230023A7 CU 2023000023 A CU2023000023 A CU 2023000023A CU 20230023 A CU20230023 A CU 20230023A CU 20230023 A7 CU20230023 A7 CU 20230023A7
Authority
CU
Cuba
Prior art keywords
chimeric antigen
immunotherapy
alzheimer
disease
tau
Prior art date
Application number
CU2023000023A
Other languages
English (en)
Inventor
Romero Mónica Bequet
Arcia Karen Leon
Armenteros Mailen López
DÍAZ Yanelys MORERA
Leal Gabriela Pérez
Valdespino Roberto Yoanky Ponce
Alvarez Heidi Quintero
Mojena Yaimee Vázquez
Loyarte Diana Iris Zamora
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Centro De Neurociencias De Cuba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia, Centro De Neurociencias De Cuba filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2023000023A priority Critical patent/CU20230023A7/es
Priority to PCT/CU2024/050004 priority patent/WO2024235367A1/es
Priority to MX2025013536A priority patent/MX2025013536A/es
Priority to EP24745882.1A priority patent/EP4725499A1/en
Publication of CU20230023A7 publication Critical patent/CU20230023A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente invención se relaciona con los sectores biomédicos y biofarmacéutico. Específicamente se refiere a un antígeno quimérico que comprende Ia combinación de las regiones amino y carboxilo terminales del péptido beta amiloide (Aβ), las regiones amino y carboxilo terminales de Ia proteína tau y un epítopo de células T. La composición farmacéutica que comprende este antígeno quimérico y al menos un adyuvante vacunal farmacéuticamente aceptable incrementa Ia eficacia de Ia inmunoterapia para Ia prevención y el tratamiento de Ia Enfermedad de Alzheimer (EA). El antígeno quimérico ejerce su acción mediante Ia estimulación de una respuesta humoral multiblanco con altos títulos de anticuerpos anti-Aβ y anti-tau simultáneamente. Con ello, se favorece Ia eliminación combinada de las especies tóxicas tanto de Aβ como de tau del cerebro lo que previene o mejora significativamente los síntomas clínicos y neuropatología de Ia EA.</p>
CU2023000023A 2023-05-12 2023-05-12 Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer CU20230023A7 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CU2023000023A CU20230023A7 (es) 2023-05-12 2023-05-12 Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer
PCT/CU2024/050004 WO2024235367A1 (es) 2023-05-12 2024-05-11 Proteína quimérica multiblanco para la inmunoterapia de la enfermedad de alzheimer
MX2025013536A MX2025013536A (es) 2023-05-12 2024-05-11 Proteina quimerica multiblanco para la inmunoterapia de la enfermedad de alzheimer
EP24745882.1A EP4725499A1 (en) 2023-05-12 2024-05-11 Multitarget chimeric protein for immunotherapy of alzheimer's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2023000023A CU20230023A7 (es) 2023-05-12 2023-05-12 Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer

Publications (1)

Publication Number Publication Date
CU20230023A7 true CU20230023A7 (es) 2024-12-09

Family

ID=91961991

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2023000023A CU20230023A7 (es) 2023-05-12 2023-05-12 Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer

Country Status (4)

Country Link
EP (1) EP4725499A1 (es)
CU (1) CU20230023A7 (es)
MX (1) MX2025013536A (es)
WO (1) WO2024235367A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
JP6713640B2 (ja) 2015-10-22 2020-06-24 免疫療法開発株式会社 アミロイドβ及びタウに対するＤＮＡワクチン
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
KR20230080397A (ko) 2020-08-07 2023-06-07 오타이르 프로테나 리미티드 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신

Also Published As

Publication number Publication date
EP4725499A1 (en) 2026-04-15
WO2024235367A1 (es) 2024-11-21
MX2025013536A (es) 2026-02-03
WO2024235367A4 (es) 2025-03-13

Similar Documents

Publication Publication Date Title
Li et al. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain
CN102123727B (zh) 用于治疗β-淀粉样变的化合物
US20220340646A1 (en) Therapeutic agent or prophylactic agent for dementia
ES2962346T3 (es) Mimotopo
ES2423590T3 (es) Tratamiento de la enfermedad de Alzheimer
CA2633399C (en) Therapeutic vaccine
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson&#39;s disease
KR20120004994A (ko) 치료적 이용 방법
Liu et al. The characteristics of astrocyte on Aβ clearance altered in Alzheimer’s disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate
JP2018524370A5 (ja) 抗ピログルタミン酸化アミロイドβヒト化抗体
Wang et al. Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice
JPWO2008133208A1 (ja) ペプチド免疫応答増強方法
Menéndez-González et al. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials
JPWO2010044464A1 (ja) 改変アミロイドβペプチド
JP2021512100A5 (es)
CU20230023A7 (es) Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer
WO2015165961A1 (en) Treatment and prevention of alzheimer&#39;s disease (ad)
JP2025506472A (ja) 抗アルファシヌクレイン治療的ワクチン
MX2022011199A (es) Peptidos ciclicos.
CA3029654A1 (en) Amino acid copolymer compositions and uses thereof
Padilla-Zambrano et al. The prion-like properties of amyloid-beta peptide and tau: Is there any risk of transmitting Alzheimer's disease during neurosurgical interventions?
Fleming Optimization and analysis of structure-based prion vaccines in transgenic mouse models
EA051687B1 (ru) Терапевтические вакцины против альфа-синуклеина
Verdoliva et al. Simplified β-amyloid peptides for safer Alzheimer’s vaccines development
HK40031828A (en) Therapeutic agent or prophylactic agent for dementia